1921
Volume 90, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Kala-azar or visceral leishmaniasis, found mostly throughout the Indian Subcontinent, East Africa, and Brazil, kills 20,000–40,000 persons annually. The agents, and , are obligatory intracellular protozoa of mononuclear phagocytes found principally in the spleen and bone marrow. Protracted fever, anemia, wasting, hepatosplenomegaly, hemorrhages, and bacterial co-infections are typical features. One hundred and twenty-two (122) in-hospital patients were studied to verify if higher bone marrow parasite load estimated by quantitative polymerase chain reaction is associated with severe disease. The estimated median parasite load was 5.0 parasites/10 human nucleated cells. It is much higher in deceased than among survivors (median 75.0 versus 4.2). Patients who lost more weight had a higher parasite burden, as well as patients with epistaxis, abdominal pain, edema, and jaundice. This study suggests that higher parasite load is influenced by wasting, which may lead to more severe disease.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0376
2014-04-02
2017-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/90/4/621.html?itemId=/content/journals/10.4269/ajtmh.13-0376&mimeType=html&fmt=ahah

References

  1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team; , 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7: e35671.[Crossref]
  2. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL, , 1996. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 124: 664672.[Crossref]
  3. Sampaio MJ, Cavalcanti NV, Alves JG, Filho MJ, Correia JB, , 2010. Risk factors for death in children with visceral leishmaniasis. PLoS Negl Trop Dis 4: e877.[Crossref]
  4. Seaman J, Mercer AJ, Sondorp E, , 1996. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 25: 862871.[Crossref]
  5. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH, , 2003. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 31: 174177.
  6. Collin SD, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, Davies C, , 2004. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 38: 612619.[Crossref]
  7. Kager PA, Rees PH, , 1986. Hematological investigations in visceral leishmaniasis. Trop Geogr Med 38: 371379.
  8. Mishra P, Dixit A, Chatterjee T, Bhattacharya M, Bhattacharya J, Dutta P, Mahapatra M, Pati HP, Choudhry VP, Saxena R, , 2004. Disseminated intravascular coagulation as an unusual presentation of kala-azar: report of two cases. Scand J Infect Dis 36: 519521.[Crossref]
  9. Lomtadze ML, Khochava MA, Shalamberidze IA, Kharaishvili VI, Vorob'eva EO, , 2005. Study of intravascular coagulation activation markers in patients with visceral leishmaniasis. Georgian Med News 140: 4750.
  10. Andrade TM, Carvalho EM, Rocha H, , 1990. Bacterial infections in patients with visceral leishmaniasis. J Infect Dis 162: 13541359.[Crossref]
  11. Barral-Netto M, Diez R, Badaro R, Sampaio D, Barral A, Carvalho EM, Falcoff E, , 1989. Serum interferon activity of patients with leishmaniasis. Braz J Med Biol Res 22: 14851487.
  12. Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD, Jr, 1989. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 83: 860864.[Crossref]
  13. Dutra M, Martinelli R, de Carvalho EM, Rodrigues LE, Brito E, Rocha H, , 1985. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 6: 2227.[Crossref]
  14. Duarte MI, Silva MR, Goto H, Nicodemo EL, Amato Neto V, , 1983. Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 77: 531537.[Crossref]
  15. Duarte MI, Corbett CE, , 1987. Histopathological patterns of the liver involvement in visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 29: 131136.[Crossref]
  16. Duarte MI, da Matta VL, Corbett CE, Laurenti MD, Chebabo R, Goto H, , 1989. Interstitial pneumonitis in human visceral leishmaniasis. Trans R Soc Trop Med Hyg 83: 7376.[Crossref]
  17. Ho EA, Soong TH, Li Y, , 1948. Comparative merits of sternum, spleen and liver punctures in the study of human visceral leishmaniasis. Trans R Soc Trop Med Hyg 41: 629636.[Crossref]
  18. Veress B, Omer A, Satir AA, El Hassan AM, , 1977. Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology 33: 605610.
  19. Ponce C, Ponce E, Morrison A, Cruz A, Kreutzer R, McMahon-Pratt D, Neva F, , 1991. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet 337: 6770.[Crossref]
  20. Rohrs LC, , 1964. Leishmaniasis in the Sudan Republic. Xviii. Parasitemia in kala-azar. Am J Trop Med Hyg 13: 265271.
  21. Kumar PV, Vasei M, Sadeghipour A, Sadeghi E, Soleimanpour H, Mousavi A, Tabatabaei AH, Rizvi MM, , 2007. Visceral leishmaniasis: bone marrow biopsy findings. J Pediatr Hematol Oncol 29: 7780.[Crossref]
  22. Molina R, Canavate C, Cercenado E, Laguna F, Lopez-Velez R, Alvar J, , 1994. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus . Aids 8: 277279.[Crossref]
  23. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P, , 2008. Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquire Immune Defic Syndr 48: 1319.[Crossref]
  24. Ho JL, He SH, Rios MJ, Wick EA, , 1992. Interleukin-4 inhibits human macrophage activation by tumor necrosis factor, granulocyte-monocyte colony-stimulating factor, and interleukin-3 or antileishmanial activity and oxidative burst capacity. J Infect Dis 165: 344351.[Crossref]
  25. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, Hashim FA, Hag-Ali M, Neva FA, Nutman TB, Sacks DL, , 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 91: 16441648.[Crossref]
  26. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG, , 1994. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 59495956.
  27. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, Costa J, Barral-Netto M, Barral A, , 2005. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113.[Crossref]
  28. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva L de A, Rabello A, Teixeira-Carvalho A, Figueiredo RM, Guimarães-Carvalho SF, Ferrari TC, Van Weyenbergh J, Correa-Oliveira R, , 2005. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 62: 487495.[Crossref]
  29. Costa DL, Rocha RL, Carvalho RM, Lima-Neto AS, Harhay MO, Costa CH, Barral-Neto M, Barral AP, , 2013. Serum cytokines associated with severity and complications of kala-azar. Pathog Glob Health 107: 7887.[Crossref]
  30. Bain BJ, , 2001. Bone marrow aspiration. J Clin Pathol 54: 657663.[Crossref]
  31. Shaw JJ, Ishikawa EA, Lainson R, , 1989. A rapid and sensitive method for the identification of Leishmania with monoclonal antibodies using fluorescein-labeled avidin. Tran R Soc Trop Med Hyg 83: 783784.[Crossref]
  32. Jaffe CL, McMahon-Pratt D, , 1987. Serodiagnostic assay for visceral leishmaniasis employing monoclonal antibodies. Trans R Soc Trop Med Hyg 81: 587594.[Crossref]
  33. Pratt DM, David JR, , 1981. Monoclonal antibodies that distinguish between New World species of Leishmania . Nature 291: 581583.[Crossref]
  34. Rolao N, Cortes S, Rodrigues OR, Campino L, , 2004. Quantification of Leishmania infantum parasites in tissue biopsies by real-time polymerase chain reaction and polymerase chain reaction-enzyme-linked immunosorbent assay. J Parasitol 90: 11501154.[Crossref]
  35. Mary C, Faraut F, Lascombe L, Dumon H, , 2004. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 42: 52495255.[Crossref]
  36. Grover Z, Ee LC, , 2009. Protein energy malnutrition. Pediatr Clin North Am 56: 10551068.[Crossref]
  37. Delgado J, Pineda JA, Macias J, Regordan C, Gallardo JA, Leal M, Sanchez-Quijano A, Lissen E, , 1998. Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. J Clin Microbiol 36: 315316.
  38. Costa CH, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, Cavalcanti JC, Santos LS, , 2010. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study. Rev Soc Bras Med Trop 43: 386392.[Crossref]
  39. Santos-Oliveira JR, Regis EG, Leal CR, Cunha RV, Bozza PT, Da-Cruz AM, , 2011. Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl Trop Dis 5: e1198.[Crossref]
  40. Smith DF, Peacock CS, Cruz AK, , 2007. Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int J Parasitol 37: 11731186.[Crossref]
  41. Lambertz U, Silverman JM, Nandan D, McMaster WR, Clos J, Foster LJ, Reiner NE, , 2012. Secreted virulence factors and immune evasion in visceral leishmaniasis. J Leukoc Biol 91: 887899.[Crossref]
  42. Frade AF, Oliveira LC, Costa DL, Costa CH, Aquino D, Van Weyenbergh J, Barral-Netto M, Barral A, Kalil J, Goldberg AC, , 2011. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral leishmaniasis. Infection, genetics and evolution. Infect Genet Evol 11: 912916.[Crossref]
  43. Alonso DP, Ferreira AF, Ribolla PE, de Miranda Santos IK, do Socorro Pires e Cruz M, Aecio de Carvalho F, Abatepaulo AR, Lamounier Costa D, Werneck GL, Farias TJ, Soares MJ, Costa CH, , 2007. Genotypes of the mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications. J Infect Dis 195: 12121217.[Crossref]
  44. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, Salotra P, , 2010. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PLoS ONE 5: e10107.[Crossref]
  45. Nylen S, Sacks D, , 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378384.[Crossref]
  46. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM, Reed SG, , 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324329.[Crossref]
  47. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, Rai M, Sundar S, Sacks D, , 2011. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis 204: 11341137.[Crossref]
  48. Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, Zhou J, Zhang LM, Liu SL, , 2012. Bone marrow and the control of immunity. Cell Mol Immunol 9: 1119.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0376
Loading
/content/journals/10.4269/ajtmh.13-0376
Loading

Data & Media loading...

  • Received : 25 Jun 2013
  • Accepted : 26 Dec 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error